Last reviewed · How we verify
La Fundacion Favaloro para la Investigacion y la Docencia Medica — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Flu Vaccine | Flu Vaccine | marketed | Prophylactic vaccine | Influenza A and B viral hemagglutinin and neuraminidase surface antigens | Immunology |
Therapeutic area mix
- Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Fondazione IRCCS Policlinico San Matteo di Pavia · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Murdoch Childrens Research Institute · 1 shared drug class
- National Cancer Institute (NCI) · 1 shared drug class
- Peking Union Medical College Hospital · 1 shared drug class
- Shanghai Zerun Biotechnology Co.,Ltd · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for La Fundacion Favaloro para la Investigacion y la Docencia Medica:
- La Fundacion Favaloro para la Investigacion y la Docencia Medica pipeline updates — RSS
- La Fundacion Favaloro para la Investigacion y la Docencia Medica pipeline updates — Atom
- La Fundacion Favaloro para la Investigacion y la Docencia Medica pipeline updates — JSON
Cite this brief
Drug Landscape (2026). La Fundacion Favaloro para la Investigacion y la Docencia Medica — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/la-fundacion-favaloro-para-la-investigacion-y-la-docencia-medica. Accessed 2026-05-17.